Blog

The Kings Fund QMR

What does last year’s NHS spend on pharma look like?

What does last year’s NHS spend on pharma look like?

Reporting by The King’s Fund this year, revealed that total NHS spending on medicines in England rose from around £13 billion in 2010/11 to £17.4 billion in 2016/17. It also revealed that the average reported growth of around 5 per cent a year is outstripping growth in the total NHS budget.

What do these numbers look like?

As specialists in managing and enhancing large and difficult to interpret datasets, we used our next-generation toolkit, RX Analyser, to create a clear, visual interpretation of last year’s NHS pharma spend.

Drilling down to details

When looking at how the health service controls spending on medicines, the King’s Fund reports increased controls on spending and promoting value for money.

A key part of the new guidance is that “low-value medicines (e.g., herbal treatments and some painkillers) and products that are widely available over the counter (e.g., for minor illnesses such as coughs and colds) shouldn’t be routinely prescribed in primary care.”

NHS Medicines Provision

Actionable analytics at your fingertips

Inspiremed provides powerful data analytics to clients in companies across the healthcare sector. We can help you to make analytics simple and can provide specialist help with your prescribing-related questions.

With our data-driven approach that gives robust, pragmatic and accurate real world analysis, you can build your business strategy with confidence, replacing estimates and guess work with proven facts and figures.

Find out more

Are you ready to gain market analytics and valuable insights – and make swift responses to market changes with ease?

To learn more and book your demonstration
info@inspire-med.co.uk
01600 891594

 

“Rx Analyser is already having a significant impact on our business, allowing our Territory Managers to focus on established CCG accounts and identify practice level successes and others for further development.”

Managing Director, UK Diabetes Healthcare Company

“The budget impact models are a real benefit.”

National Sales Manager, UK Pharmaceutical Company

“The feature I like most? The ability to drill down to competitor sales.”

Senior Manager, Global Healthcare Company, 2016

“The level of analysis and insight gained from use of Rx Analyser is non-comparable. Customer segmentation, targeting and development of compelling value propositions is much more straightforward.”

Sales and Marketing Manager, Leading Healthcare Company, 2016

“We are working in an ever evolving industry where data increasingly drives marketing and sales activity. I believe RX Analyser is the most comprehensive analytics tool available for prescription data analysis. I can already see other business areas (within my company) that could really benefit.”

Sales and Marketing Manager, Leading Healthcare Company, 2016

“Key benefits? Adaptability, flexibility for future changes and cloud-based.”

General Manager, Global Healthcare Company

Sign up for added insights